Interim Report January - March 2022
Curasight A/S (“Curasight” or “the Company” - TICKER: CURAS) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “Curasight began the year by accomplishing several essential milestones and strengthening its position as a theranostic company. Among the highlights are the positive results from the investigator-initiated phase IIb studies regarding Neuroendocrine tumors (NET) and granting